Dr. Steve Greene and Dr. C. Michael Gibson examine the differences between steroidal and nonsteroidal MRAs, the contrasting findings from randomized clinical trials, and the 2026 Expert Consensus Decision Pathway (ECDP) guidance on optimizing treatment with SGLT2 inhibitors and finerenone in patients with HFpEF.